Abstract
Introduction
Although the respiratory market has expanded considerably from 2004 to 2008,
growth in the seven major markets is slowing down from 2009 to 2011, after
which sales will decline due to patent expiries of leading brands. Growth is
driven by the expansion of sales in existing classes, the launch of major new
products with safety and convenience advantages, and the results of several
landmark trials.
Key reasons to purchase this research
- Identify key opportunities and threats that will impact the use and uptake
of new and existing products
- Quantify the future size and scope of the asthma/COPD market and predict
the performance of key compounds
- Understand critical success factors in growing and defending respiratory
brand franchises from new entrants and generics
Table of Contents
OVERVIEW
- This product contains forecasts for asthma and COPD drugs across the seven
major markets from 2009 to 2018. It has been designed for delivery in an excel
data pack format, but for more detail about this asthma and COPD please see
the accompanying Commercial Insight: Asthma and COPD word document and
PowerPoint executive presentation (DMHC2520).
- The associated report and PowerPoint presentation can be found under
Latest research in the Knowledge centre, through the search function or by
contacting your sales representative.
- Please select the data pack option from the download menu at the side of
the page to access the model.
- Introduction
- Research and analysis highlights
- Key reasons to read this report
- Forecasting Methodology
- The forecasting model:
- General event information:
- Event selection and quantification:
- Event parameters:
| 
